Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 253

1.

Putative cis-regulatory drivers in colorectal cancer.

Ongen H, Andersen CL, Bramsen JB, Oster B, Rasmussen MH, Ferreira PG, Sandoval J, Vidal E, Whiffin N, Planchon A, Padioleau I, Bielser D, Romano L, Tomlinson I, Houlston RS, Esteller M, Orntoft TF, Dermitzakis ET.

Nature. 2014 Jul 23. doi: 10.1038/nature13602. [Epub ahead of print]

PMID:
25079323
[PubMed - as supplied by publisher]
2.

Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.

Wesołowska-Andersen A, Borst L, Dalgaard MD, Yadav R, Rasmussen KK, Wehner PS, Rasmussen M, Orntoft TF, Nordentoft I, Koehler R, Bartram CR, Schrappe M, Sicheritz-Ponten T, Gautier L, Marquart H, Madsen HO, Brunak S, Stanulla M, Gupta R, Schmiegelow K.

Leukemia. 2014 Jul 3. doi: 10.1038/leu.2014.205. [Epub ahead of print]

PMID:
24990611
[PubMed - as supplied by publisher]
3.

External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Cabayo M, Szarvas T, Zwarthoff EC, Lokeswhar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Jun 11. pii: cebp.0029.2014. [Epub ahead of print]

PMID:
24920641
[PubMed - as supplied by publisher]
4.

Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

Vedder MM, Márquez M, de Bekker-Grob EW, Calle ML, Dyrskjøt L, Kogevinas M, Segersten U, Malmström PU, Algaba F, Beukers W, Ørntoft TF, Zwarthoff E, Real FX, Malats N, Steyerberg EW.

PLoS One. 2014 Jun 6;9(6):e96849. doi: 10.1371/journal.pone.0096849. eCollection 2014.

PMID:
24905984
[PubMed - in process]
Free PMC Article
5.

Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer.

Christensen LL, Holm A, Rantala J, Kallioniemi O, Rasmussen MH, Ostenfeld MS, Dagnaes-Hansen F, Øster B, Schepeler T, Tobiasen H, Thorsen K, Sieber OM, Gibbs P, Lamy P, Hansen TF, Jakobsen A, Riising EM, Helin K, Lubinski J, Hagemann-Madsen R, Laurberg S, Ørntoft TF, Andersen CL.

PLoS One. 2014 Jun 3;9(6):e96767. doi: 10.1371/journal.pone.0096767. eCollection 2014.

PMID:
24892549
[PubMed - in process]
Free PMC Article
6.

Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.

Hedegaard J, Thorsen K, Lund MK, Hein AM, Hamilton-Dutoit SJ, Vang S, Nordentoft I, Birkenkamp-Demtröder K, Kruhøffer M, Hager H, Knudsen B, Andersen CL, Sørensen KD, Pedersen JS, Ørntoft TF, Dyrskjøt L.

PLoS One. 2014 May 30;9(5):e98187. doi: 10.1371/journal.pone.0098187. eCollection 2014.

PMID:
24878701
[PubMed - in process]
Free PMC Article
7.

Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications.

Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C.

Eur Urol. 2014 May 2. pii: S0302-2838(14)00395-9. doi: 10.1016/j.eururo.2014.04.014. [Epub ahead of print] Review.

PMID:
24836153
[PubMed - as supplied by publisher]
8.

Mutational context and diverse clonal development in early and late bladder cancer.

Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Høyer S, Borre M, Reinert T, Fristrup N, Dyrskjøt L, Shah S, Pedersen JS, Ørntoft TF.

Cell Rep. 2014 Jun 12;7(5):1649-63. doi: 10.1016/j.celrep.2014.04.038. Epub 2014 May 15.

PMID:
24835989
[PubMed - in process]
Free Article
9.

Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Clin Cancer Res. 2014 Apr 15;20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642.

PMID:
24737792
[PubMed - in process]
10.

Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation.

Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V, Lebenthal-Loinger I, Stein I, Reich R, Beenstock J, Zehorai E, Andersen CL, Thorsen K, Orntoft TF, Davis RJ, Davidson B, Mu D, Karni R.

Cell Rep. 2014 Apr 24;7(2):501-13. doi: 10.1016/j.celrep.2014.03.041. Epub 2014 Apr 13.

PMID:
24726367
[PubMed - in process]
Free Article
11.

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.

Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardus A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martinez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Vander Heiden MG, Albar JP, Esteller M.

Nat Commun. 2014 Apr 3;5:3608. doi: 10.1038/ncomms4608.

PMID:
24699711
[PubMed - in process]
Free PMC Article
12.

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.

Teo MT, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE.

Ann Oncol. 2014 Apr;25(4):877-83. doi: 10.1093/annonc/mdu014. Epub 2014 Mar 12.

PMID:
24623370
[PubMed - in process]
Free PMC Article
13.

Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.

Jeppesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjøt L, Ørntoft TF, Larsen MR, Ostenfeld MS.

Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.

PMID:
24376083
[PubMed - in process]
14.

Identification of expressed and conserved human noncoding RNAs.

Nielsen MM, Tehler D, Vang S, Sudzina F, Hedegaard J, Nordentoft I, Orntoft TF, Lund AH, Pedersen JS.

RNA. 2014 Feb;20(2):236-51. doi: 10.1261/rna.038927.113. Epub 2013 Dec 16.

PMID:
24344320
[PubMed - indexed for MEDLINE]
15.

Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells.

Birkenkamp-Demtröder K, Hahn SA, Mansilla F, Thorsen K, Maghnouj A, Christensen R, Øster B, Ørntoft TF.

PLoS One. 2013 Sep 9;8(9):e73593. doi: 10.1371/journal.pone.0073593. eCollection 2013.

PMID:
24039993
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

PMID:
24018021
[PubMed - in process]
17.

DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.

Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Høyer S, Orntoft TF, Sørensen KD.

J Clin Oncol. 2013 Sep 10;31(26):3250-8. doi: 10.1200/JCO.2012.47.1847. Epub 2013 Aug 5.

PMID:
23918943
[PubMed - indexed for MEDLINE]
18.

A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.

Kandimalla R, Masius R, Beukers W, Bangma CH, Orntoft TF, Dyrskjot L, van Leeuwen N, Lingsma H, van Tilborg AA, Zwarthoff EC.

Clin Cancer Res. 2013 Sep 1;19(17):4760-9. doi: 10.1158/1078-0432.CCR-12-3276. Epub 2013 Jul 10.

PMID:
23842048
[PubMed - indexed for MEDLINE]
19.

[New scientific society--Danish Society for Molecular Medicine--established in spring 2012].

Ørntoft TF.

Ugeskr Laeger. 2013 Mar 18;175(12):813. Danish. No abstract available.

PMID:
23582819
[PubMed - indexed for MEDLINE]
20.

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL.

Mol Oncol. 2013 Jun;7(3):637-46. doi: 10.1016/j.molonc.2013.02.016. Epub 2013 Feb 28.

PMID:
23506979
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk